Dashboard
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
3
The company has declared Negative results for the last 12 consecutive quarters
4
Risky - Negative EBITDA
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 4,890 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.60
-122.95%
5.53
Revenue and Profits:
Net Sales:
76 Million
(Quarterly Results - Jun 2025)
Net Profit:
-167 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.88%
0%
-3.88%
6 Months
-22.66%
0%
-22.66%
1 Year
3.12%
0%
3.12%
2 Years
-33.11%
0%
-33.11%
3 Years
-60.87%
0%
-60.87%
4 Years
-57.69%
0%
-57.69%
5 Years
-66.55%
0%
-66.55%
D. Western Therapeutics Institute, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.08%
EBIT Growth (5y)
-261.93%
EBIT to Interest (avg)
-152.17
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.23
Tax Ratio
0.14%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.43
EV to EBIT
-4.65
EV to EBITDA
-4.88
EV to Capital Employed
12.96
EV to Sales
10.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-278.61%
ROE (Latest)
-105.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
76.50
96.80
-20.97%
Operating Profit (PBDIT) excl Other Income
-155.10
-130.30
-19.03%
Interest
2.10
1.90
10.53%
Exceptional Items
0.20
0.80
-75.00%
Consolidate Net Profit
-166.70
-150.20
-10.99%
Operating Profit Margin (Excl OI)
-2,183.80%
-1,467.60%
-71.62%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -20.97% vs -21.11% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -10.99% vs 73.33% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
471.60
428.40
10.08%
Operating Profit (PBDIT) excl Other Income
-1,159.90
-749.80
-54.69%
Interest
5.20
2.50
108.00%
Exceptional Items
-60.60
-30.40
-99.34%
Consolidate Net Profit
-1,290.30
-828.40
-55.76%
Operating Profit Margin (Excl OI)
-2,564.30%
-1,864.20%
-70.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 10.08% vs -4.40% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -55.76% vs -87.46% in Dec 2023
About D. Western Therapeutics Institute, Inc. 
D. Western Therapeutics Institute, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






